scilogo.jpg
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
29 juin 2022 08h30 HE | SciSparc Ltd
TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
23 juin 2022 09h30 HE | SciSparc Ltd
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
scilogo.jpg
SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins
15 juin 2022 08h30 HE | SciSparc Ltd
JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty,...
scilogo.jpg
SciSparc's Board of Directors Provides Strategic Decision
09 juin 2022 08h30 HE | SciSparc Ltd
TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of...
scilogo.jpg
SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.
07 juin 2022 08h30 HE | SciSparc Ltd
TEL AVIV, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
scilogo.jpg
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
02 juin 2022 08h30 HE | SciSparc Ltd
No dedicated treatment currently available for cocaine addiction TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical...
scilogo.jpg
SciSparc Ltd. Announces Closing of $10 Million Private Placement Priced At-the-Market
01 juin 2022 16h07 HE | SciSparc Ltd
TEL AVIV, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
31 mai 2022 08h30 HE | SciSparc Ltd
SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology TEL AVIV, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
scilogo.jpg
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
27 mai 2022 09h15 HE | SciSparc Ltd
TEL AVIV, Israel, May 27, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
26 mai 2022 08h30 HE | SciSparc Ltd
Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel TEL AVIV, Israel, May 26, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC)...